, part of Novozymes A/S, announced a collaboration with Almac, to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements. The collaboration will allow clients to use Almac’s manufacturing assets and protein conjugation capability to link Novozymes’ Recombumin Flex technology to their peptide and small molecule drugs. Collaborations with commercial partners have already begun and will continue to expand in early 2014.
Novozymes has modified the amino acid sequence of human albumin to increase its receptor affinity, providing properties including improved half-life extension and drug targeting. This technology supplements Almac’s knowledge in peptide and small molecule manufacturing, and can also be associated to its protein conjugation technology offerings. As a result, clients will be able to use Almac’s technology to link Recombumin Flex to their drug products as part of a contract service offering.
Source: Novozymes Biopharma